At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
MCS110 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
In Brief
A Phase 2 clinical trial evaluating MCS110, carboplatin, and 1 other intervention for Advanced Triple Negative Breast Cancer (TNBC) With High TAMs. Completed, enrolled 50 participants across 23 sites in 12 countries.
Detailed Summary
To determine whether MCS110 antibody therapy improves the efficacy of carboplatin and gemcitabine (carbo/gem) in advanced TNBC patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Austria, Belgium, France, Germany, Hong Kong, Italy, South Korea, Spain, Taiwan, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartAug 2015
Primary CompletionJan 2020
Study CompletionMar 2020
TodayJul 2026
First PostedMay 6, 2015
Enrollment StartAug 10, 2015
Primary CompletionJan 4, 2020
Study CompletionMar 23, 2020
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 11.2 years ago
Interventions
MCS110drug
taken by I.V
carboplatindrug
taken by I.V
gemcitabinedrug
taken by I.V